Britannia Pharmaceuticals Ltd.
Privately held: no public share price
Assets
(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Approved | Dopamine receptor (non-ergoline agonist)Small molecule | Parkinson's Disease | |
| Approved | Dopamine receptor (non-ergoline agonist)Small molecule | Parkinson's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.